San Diego Life Sciences Roundup: Illumina, Conatus, Isis, and More
(Page 2 of 2)
Advanced Liquid Logic, which has proprietary microfluidics technology that uses voltage to manipulate droplets through a sealed “Lab-on-a-chip” is an example of the kind of smaller M&A deal that Illumina would be doing in coming years.
—Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS) reported more encouraging results from a mid-stage trial of its antisense drug candidate ISIS-APOCIII Rx. In a study of 26 patients at very high-risk for cardiovascular disease and pancreatitis, Isis said its drug resulted in a 70 percent reduction in a dangerous protein, apolipoprotein C-III, and as much as a 64 percent reduction in triglycerides. The drug is meant for patients with extremely high levels of both compounds, which are closely associated with heart disease. Isis released the first batch of results for the drug about a month ago.
—San Diego-based MediciNova (NASDAQ: MNOV) said the NIH has awarded a grant that will enable the company to continue with a mid-stage trial of MN-166 (Ibudilast) in patients with progressive multiple sclerosis. MediciNova said the study will be led by Robert Fox, a staff neurologist at the Cleveland Clinic’s Mellen Center for Multiple Sclerosis, and is part of a collaboration that includes the National MS Society and MediciNova.